ClinicalTrials.gg
CompletedNCT05399485Updated Nov 18, 2025Results posted

Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)

A Phase 3 interventional study of Rimegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 44 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
496
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Enrollment
18th of 32
496 · median 618
Started
2022
with 7 others
Phase 3
14 of 32
5 open now
Registered
15th of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 18th largest by enrollment, is one of 8 that started in 2022, is one of 14 in phase 3, and was the 15th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the prevention of migraine.

03

Conditions studied

  • Migraine

Keywords

  • Migraine
  • Headache
  • Migraine Prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:

  1. Age of onset of migraines prior to 50 years of age.
  2. Migraine attacks, on average, lasting 4 to 72 hours if untreated.
  3. Per subject report, 4 to18 migraine attacks of moderate or severe intensity per month within the last 3 months prior to the Screening Visit (month is defined as 4 weeks for the purpose of this protocol).
  4. 4 or more migraine days during Observation Period.
  5. Not more than 18 headache days during the Observation Period.
  6. Ability to distinguish migraine attacks from tension/cluster headaches.
  7. Subjects on prophylactic migraine medication are permitted to remain on therapy if the dose has been stable for at least 3 months (12 weeks) prior to the Observation Period, and the dose is not expected to change during the course of the study.
  8. Subjects with for use of triptans may be included provided they meet all other study entry criteria.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a history of migraine with brainstem aura (basilar migraine), hemiplegic migraine or retinal migraine.
  2. Subjects with headaches occurring 19 or more days per month (migraine or non-migraine) in any of the 3 months prior to the Screening Visit.
  3. History of systemic use of analgesics (e.g. nonsteroidal anti-inflammatory drugs [NSAIDs] or acetaminophen) on ≥ 15 days per month during the 3 months (12 weeks) prior to the Screening Visit.
  4. Subject with a history of disease.
  5. Subject history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. subjects with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS),Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or (TIA) during the 6 months prior to screening.
  6. Uncontrolled hypertension, or uncontrolled diabetes (however subjects can be included who have stable hypertension and/or diabetes for 3 months prior to screening).
  7. Subject with other pain syndromes, psychiatric conditions, dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments.
  8. Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease that causes malabsorption.
  9. The subject has a history or current evidence of any unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known or suspected infection, or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial.
  10. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or subjects who have met criteria for any significant substance use disorder within the past 12 months from the date of the screening visit.
  11. Participation in any other clinical trial while participating in this clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
496 participants (actual)

Study arms

  • Experimental
    Rimegepant

    Randomization Phase: one 75 mg rimegepant (BHV3000) oral disintegration tablet every other day until Week 12

    Drug: Rimegepant

  • Placebo comparator
    Placebo

    Randomization Phase: one matching placebo every other day until week 12

    Drug: Placebo

Interventions

  • Randomization Phase: Rimegepant (BHV3000) 75 mg orally disintegrating tablet every other day until Week 12

    Also known as: BHV3000

  • DrugPlacebo

    Randomization Phase: Placebo tablet to match Rimegepant every other day until Week 12

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase

    Migraine day: 1) day of electronic diary (eDiary) efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more of the following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 9 to 12\])/ (total number of efficacy data days in month \[Week 9 to 12\]).

    Time frame: Baseline, Week 9 to Week 12 of the DBT phase

Secondary outcomes

  1. Percentage of Participants With at Least 50% Reduction From Baseline in the Mean Number of Moderate to Severe Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase

    Percentage of participants with \>= 50% reduction, from baseline in mean number of pain intensity (moderate or severe) in each month of DBT phase are included in this outcome measure. Migraine days per month are assessed as "migraine days per 4 weeks" to correspond with the 4-week visit schedule. Migraine days per month are based on 4-week intervals and are prorated to account for missing migraine reports. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 9 to 12\])/ (total number of efficacy data days in month \[Week 9 to 12\])

    Time frame: Baseline, Week 9 to Week 12 of the DBT phase

  2. Mean Change From Baseline in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

    Migraine day:1) day of eDiary efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. In the model analysis, this outcome was also evaluated based on the monthly number of migraine days (and estimated the migraine days per month over the entire DBT phase). The number of migraine days per month were prorated to 28 days and derived for month (i.e.,4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month/ (total number of efficacy data days in month).

    Time frame: Baseline, Week 1 to Week 12 of the DBT phase

  3. Mean Change From Baseline in Number of Migraine Days Per Month From Week 1 to 4 of the DBT Phase

    Migraine day: 1) day of eDiary efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more of the following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 1 to 4\])/ (total number of efficacy data days in month \[Week 1 to 4\]).

    Time frame: Baseline, Week 1 to Week 4 of the DBT phase

  4. Mean Number of Acute Migraine-specific Medication Days Per Month From Week 9 to 12 of the DBT Phase

    An acute migraine-specific medication day was defined as day of eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or aura. Migraine days per month are assessed as "migraine days per 4 weeks" to correspond with the 4-week visit schedule. Migraine days per month are based on 4-week intervals and are prorated to account for missing migraine reports. The number of acute migraine-specific medication days per month was prorated to 28 days and derived for month (i.e., 4-week interval) in the on-DBT efficacy analysis period: 28\*(total number of acute migraine-specific medication days in the month \[Week 9 to 12\])/ (total number of efficacy data days in the month \[Week 9 to 12\]).

    Time frame: Week 9 to Week 12 of the DBT phase

  5. Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) v 2.1 Role Function - Restrictive Domain Score at Week 12 of the DBT Phase

    MSQoL is a self-administered, 14-item instrument validated in 3 domains: role restriction, role prevention, and the emotional function. The role function-restrictive domain consists of 7 items that describe how migraine limits one's daily social and work-related activities. Participants respond to items using a 6-point scale: "none of the time," "a little bit of the time," "some of the time," "a good bit of the time," "most of the time," and "all of the time," which are assigned scores of 1 to 6, respectively. Item scores are recoded using (7 - original score). Next, raw dimension scores are computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that higher scores indicate better quality of life. The change from baseline was calculated as the MSQoL restrictive role function domain score at Week 12 of the DBT phase minus the MSQoL restrictive role function domain score at baseline.

    Time frame: Baseline, Week 12 of the DBT phase

  6. Mean Change From Baseline in the Migraine Disability Assessment Total Score (MIDAS) at Week 12 of the DBT Phase

    MIDAS is a retrospective, self-administered, 5-item questionnaire that measures headache-related disability as lost time due to headache from paid work or school, household work, and non-work activities. Participants provide the number of missed work or school days; missed household chores days; missed social or leisure activity days; and days at work or school, and separately at home, where productivity was reduced by half or more in the last 3 months (scale: 0 - 90 for each of 5 subscales). The 5 subscale scores are summed to compute the MIDAS total score (scale: 0 - 450). Lower scores indicate less headache-related disability. The change from baseline was calculated as the MIDAS total score at Week 12 of the DBT phase minus the MIDAS total score at baseline.

    Time frame: Baseline, Week 12 of the DBT phase

  7. Mean Change From Baseline in the EuroQol 5 Dimensions 5-level (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Week 12 of the DBT Phase

    EQ-5D-5L is a standardized measure of health status. The EQ-5D-5L consisted of EQ-5D-5L descriptive system and the EQ VAS. For EQ VAS participant rated their overall health status from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state.

    Time frame: Baseline, Week 12 of the DBT phase

  8. Number of Participants With Adverse Events (AEs) By Intensity in DBT Phase

    An Adverse Event (AE) was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Definition of AE in terms of intensity: Mild: Is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: Is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participant. Severe: Interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

    Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)

  9. Number of Participants With AEs By Intensity in Open-Label Extension (OLE) Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Definition of AE in terms of intensity: Mild: Is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: Is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participant. Severe: Interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

    Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)

  10. Number of Participants With Serious Adverse Events (SAEs) in DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the off spring who received rimegepant were considered an important medical event.

    Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)

  11. Number of Participants With SAEs in OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. A SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant were considered an important medical event.

    Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)

  12. Number of Participants With AEs Leading to Discontinuation of Study Drug in DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with adverse events leading to discontinuation of study drug were reported.

    Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)

  13. Number of Participants With AEs Leading to Discontinuation of Study Drug in OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with adverse events leading to discontinuation of study drug were reported.

    Time frame: From Day 1 of OL Rimegepant dosing up at Week 12 to Week 52 (40 weeks)

  14. Number of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase: Hematology Parameters

    The laboratory parameters were graded according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version (v)5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Hematology parameters included: eosinophils, hemoglobin (high, low), lymphocytes (high, low), white blood cell count (WBC) (low, high), platelets, and neutrophils. hematocrit, red blood cell count, Number of participants with non-zero laboratory abnormalities of hematology parameters were reported in this outcome measure.

    Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)

  15. Number of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase: Hematology Parameters

    The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Hematology parameters included: eosinophils, hemoglobin (high, low), lymphocytes (high, low), WBC (low, high), platelets, and neutrophils. Number of participants with non-zero laboratory abnormalities of hematology parameters were reported in this outcome measure.

    Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)

  16. Number of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase: Serum Chemistry Parameters

    The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Serum chemistry parameters included: creatine kinase, low density lipoprotein (LDL) cholesterol, LDL cholesterol, fasting, triglycerides, triglycerides, fasting and not fasting, alanine aminotransferase increased, albumin, alkaline phosphatase, aspartate aminotransferase increased, bicarbonate, bilirubin, calcium (high, low), cholesterol, creatinine, estimated glomerular filtration rate (eGFR), glucose (high, low), lactate dehydrogenase, LDL cholesterol, potassium (high, low), sodium (high, low), and uric acid. Number of participants with non-zero laboratory abnormalities of serum chemistry parameters were reported in this outcome measure.

    Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)

  17. Number of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase: Serum Chemistry Parameters

    The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Serum chemistry parameters included: creatine kinase, LDL cholesterol, LDL cholesterol, triglycerides, triglycerides, alanine aminotransferase increased, albumin, alkaline phosphatase, aspartate aminotransferase increased, bicarbonate, bilirubin, calcium (high, low), cholesterol, creatinine, eGFR, glucose (high, low), lactate dehydrogenase, potassium (high, low), sodium (high, low), uric acid. Number of participants with non-zero laboratory abnormalities of serum chemistry parameters were reported in this outcome measure.

    Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)

  18. Number of Participants With Grade 3 to 4 Changes in DBT Phase: Urinalysis

    The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Urinalysis parameters included: urine glucose and urine protein.

    Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)

  19. Number of Participants With Grade 3 to 4 Changes in OLE Phase: Urinalysis

    The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Urinalysis parameters included: urine glucose and urine protein. Number of participants with non-zero laboratory abnormalities of urinalysis parameters were reported in this outcome measure.

    Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)

  20. Number of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3* Upper Lower Limit of Normal (ULN) Concurrent With Total Bilirubin (TBIL) >2*ULN in DBT Phase

    Number of participants with ALT or AST \>3\*ULN concurrent with TBIL \>2\*ULN in DBT phase were reported in this outcome measure.

    Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)

  21. Number of Participants With ALT or AST> 3* ULN Concurrent With TBIL >2* ULN in OLE Phase

    Number of participants with ALT or AST \>3\*ULN concurrent with TBIL \>2\*ULN in OLE phase were reported in this outcome measure.

    Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)

  22. Number of Participants With Hepatic-related AEs in the DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure.

    Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)

  23. Number of Participants With Hepatic-related AEs in the OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure.

    Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)

  24. Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure. Number of participants with Hepatic-related AEs leading to study drug discontinuation were reported in this outcome measure.

    Time frame: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)

  25. Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure. Number of participants with Hepatic-related AEs leading to study drug discontinuation were reported in this outcome measure.

    Time frame: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)

07

Results

Posted Jul 14, 2025

Participant flow

DBT Phase
Participant flow — DBT Phase
MilestoneRimegepantPlacebo
Started247249
Completed233238
Not completed1411
Withdrew: Other65
Withdrew: Protocol-specified withdrawal criterion met11
Withdrew: Withdrawal by subject32
Withdrew: Protocol violation21
Withdrew: Physician decision01
Withdrew: Adverse event21
OLE Phase
Participant flow — OLE Phase
MilestoneRimegepantPlacebo
Started227231
Completed204215
Not completed2316
Withdrew: Protocol deviation10
Withdrew: Other55
Withdrew: Withdrawal by subject127
Withdrew: Pregnancy02
Withdrew: Physician decision30
Withdrew: Adverse event22

Outcome measures

PrimaryMean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase

Migraine day: 1) day of electronic diary (eDiary) efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more of the following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 9 to 12\])/ (total number of efficacy data days in month \[Week 9 to 12\]).

Time frame:
Baseline, Week 9 to Week 12 of the DBT phase
Reported as:
Least squares mean · Days/month
Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase
Days/monthRimegepantPlacebo
Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase-2.4 (-2.93 to -1.96)-1.4 (-1.87 to -0.91)
Statistical analysis
  • Rimegepant vs Placebo · Mixed Models Analysis · p = 0.0021 · [difference in least square (ls) mean]: -1.1 · 95% CI -1.73 to -0.38
SecondaryPercentage of Participants With at Least 50% Reduction From Baseline in the Mean Number of Moderate to Severe Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase

Percentage of participants with \>= 50% reduction, from baseline in mean number of pain intensity (moderate or severe) in each month of DBT phase are included in this outcome measure. Migraine days per month are assessed as "migraine days per 4 weeks" to correspond with the 4-week visit schedule. Migraine days per month are based on 4-week intervals and are prorated to account for missing migraine reports. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 9 to 12\])/ (total number of efficacy data days in month \[Week 9 to 12\])

Time frame:
Baseline, Week 9 to Week 12 of the DBT phase
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 50% Reduction From Baseline in the Mean Number of Moderate to Severe Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase
Percentage of participantsRimegepantPlacebo
Percentage of Participants With at Least 50% Reduction From Baseline in the Mean Number of Moderate to Severe Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase41.7 (35.5 to 47.9)34.4 (28.5 to 40.4)
Statistical analysis
  • Rimegepant vs Placebo · Mantel Haenszel · p = 0.0989 (P-value \>0.05; therefore, all secondary outcome measures listed after this outcome measure in the hierarchy were not tested.) · Difference in percentage: 7.3 · 95% CI -1.4 to 15.9
SecondaryMean Change From Baseline in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)

Migraine day:1) day of eDiary efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. In the model analysis, this outcome was also evaluated based on the monthly number of migraine days (and estimated the migraine days per month over the entire DBT phase). The number of migraine days per month were prorated to 28 days and derived for month (i.e.,4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month/ (total number of efficacy data days in month).

Time frame:
Baseline, Week 1 to Week 12 of the DBT phase
Reported as:
Least squares mean · Days/month
Mean Change From Baseline in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Days/monthRimegepantPlacebo
Mean Change From Baseline in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)-2.5 (-2.91 to -2.15)-1.1 (-1.47 to -0.64)
SecondaryMean Change From Baseline in Number of Migraine Days Per Month From Week 1 to 4 of the DBT Phase

Migraine day: 1) day of eDiary efficacy data with a qualified migraine headache, defined as: Headache lasted for \>= 30 minutes and had 2 or more of following pain features: Unilateral and pulsating, moderate or severe pain intensity, worsen or avoid physical activity with one or more of the following associated symptoms: nausea, vomiting, both photophobia and phonophobia or 2) Acute migraine-specific medication day as eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or non-scheduled OL Rimegepant dosing day. The number of migraine days per month were prorated to 28 days and derived for month (i.e., 4-week interval) in on-DBT efficacy analysis period as follows: 28\*(total number of migraine days in month \[Week 1 to 4\])/ (total number of efficacy data days in month \[Week 1 to 4\]).

Time frame:
Baseline, Week 1 to Week 4 of the DBT phase
Reported as:
Least squares mean · Days/month
Mean Change From Baseline in Number of Migraine Days Per Month From Week 1 to 4 of the DBT Phase
Days/monthRimegepantPlacebo
Mean Change From Baseline in Number of Migraine Days Per Month From Week 1 to 4 of the DBT Phase-2.7 (-3.11 to -2.20)-0.8 (-1.26 to -0.32)
SecondaryMean Number of Acute Migraine-specific Medication Days Per Month From Week 9 to 12 of the DBT Phase

An acute migraine-specific medication day was defined as day of eDiary efficacy data with a "yes" response to either of the 2 questions about taking triptan or ergotamine to treat headache or aura. Migraine days per month are assessed as "migraine days per 4 weeks" to correspond with the 4-week visit schedule. Migraine days per month are based on 4-week intervals and are prorated to account for missing migraine reports. The number of acute migraine-specific medication days per month was prorated to 28 days and derived for month (i.e., 4-week interval) in the on-DBT efficacy analysis period: 28\*(total number of acute migraine-specific medication days in the month \[Week 9 to 12\])/ (total number of efficacy data days in the month \[Week 9 to 12\]).

Time frame:
Week 9 to Week 12 of the DBT phase
Reported as:
Least squares mean · Days/month
Mean Number of Acute Migraine-specific Medication Days Per Month From Week 9 to 12 of the DBT Phase
Days/monthRimegepantPlacebo
Mean Number of Acute Migraine-specific Medication Days Per Month From Week 9 to 12 of the DBT Phase5.0 (4.40 to 5.55)5.8 (5.24 to 6.40)
SecondaryMean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) v 2.1 Role Function - Restrictive Domain Score at Week 12 of the DBT Phase

MSQoL is a self-administered, 14-item instrument validated in 3 domains: role restriction, role prevention, and the emotional function. The role function-restrictive domain consists of 7 items that describe how migraine limits one's daily social and work-related activities. Participants respond to items using a 6-point scale: "none of the time," "a little bit of the time," "some of the time," "a good bit of the time," "most of the time," and "all of the time," which are assigned scores of 1 to 6, respectively. Item scores are recoded using (7 - original score). Next, raw dimension scores are computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that higher scores indicate better quality of life. The change from baseline was calculated as the MSQoL restrictive role function domain score at Week 12 of the DBT phase minus the MSQoL restrictive role function domain score at baseline.

Time frame:
Baseline, Week 12 of the DBT phase
Reported as:
Least squares mean · Score on a scale
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) v 2.1 Role Function - Restrictive Domain Score at Week 12 of the DBT Phase
Score on a scaleRimegepantPlacebo
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) v 2.1 Role Function - Restrictive Domain Score at Week 12 of the DBT Phase7.8 (6.20 to 9.44)3.7 (2.05 to 5.36)
SecondaryMean Change From Baseline in the Migraine Disability Assessment Total Score (MIDAS) at Week 12 of the DBT Phase

MIDAS is a retrospective, self-administered, 5-item questionnaire that measures headache-related disability as lost time due to headache from paid work or school, household work, and non-work activities. Participants provide the number of missed work or school days; missed household chores days; missed social or leisure activity days; and days at work or school, and separately at home, where productivity was reduced by half or more in the last 3 months (scale: 0 - 90 for each of 5 subscales). The 5 subscale scores are summed to compute the MIDAS total score (scale: 0 - 450). Lower scores indicate less headache-related disability. The change from baseline was calculated as the MIDAS total score at Week 12 of the DBT phase minus the MIDAS total score at baseline.

Time frame:
Baseline, Week 12 of the DBT phase
Reported as:
Least squares mean · Score on a scale
Mean Change From Baseline in the Migraine Disability Assessment Total Score (MIDAS) at Week 12 of the DBT Phase
Score on a scaleRimegepantPlacebo
Mean Change From Baseline in the Migraine Disability Assessment Total Score (MIDAS) at Week 12 of the DBT Phase-4.0 (-5.57 to -2.42)-1.6 (-3.88 to 0.70)
SecondaryMean Change From Baseline in the EuroQol 5 Dimensions 5-level (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Week 12 of the DBT Phase

EQ-5D-5L is a standardized measure of health status. The EQ-5D-5L consisted of EQ-5D-5L descriptive system and the EQ VAS. For EQ VAS participant rated their overall health status from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state.

Time frame:
Baseline, Week 12 of the DBT phase
Reported as:
Least squares mean · Score on a scale
Mean Change From Baseline in the EuroQol 5 Dimensions 5-level (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Week 12 of the DBT Phase
Score on a scaleRimegepantPlacebo
Mean Change From Baseline in the EuroQol 5 Dimensions 5-level (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Week 12 of the DBT Phase3.5 (1.60 to 5.37)0.8 (-1.40 to 3.02)
SecondaryNumber of Participants With Adverse Events (AEs) By Intensity in DBT Phase

An Adverse Event (AE) was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Definition of AE in terms of intensity: Mild: Is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: Is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participant. Severe: Interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

Time frame:
From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) By Intensity in DBT Phase
ParticipantsRimegepantPlacebo
Any AE135102
Mild AE11096
Moderate AE246
Severe AE10
SecondaryNumber of Participants With AEs By Intensity in Open-Label Extension (OLE) Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Definition of AE in terms of intensity: Mild: Is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate: Is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participant. Severe: Interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

Time frame:
From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Reported as:
Count of participants · Participants
Number of Participants With AEs By Intensity in Open-Label Extension (OLE) Phase
ParticipantsDBT Rimegepant/OLE RimegepantDBT Placebo/OLE Rimegepant
Any AE162175
Mild AE127141
Moderate AE3333
Severe AE21
SecondaryNumber of Participants With Serious Adverse Events (SAEs) in DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the off spring who received rimegepant were considered an important medical event.

Time frame:
From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) in DBT Phase
ParticipantsRimegepantPlacebo
Number of Participants With Serious Adverse Events (SAEs) in DBT Phase21
SecondaryNumber of Participants With SAEs in OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. A SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant were considered an important medical event.

Time frame:
From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Reported as:
Count of participants · Participants
Number of Participants With SAEs in OLE Phase
ParticipantsDBT Rimegepant/OLE RimegepantDBT Placebo/OLE Rimegepant
Number of Participants With SAEs in OLE Phase40
SecondaryNumber of Participants With AEs Leading to Discontinuation of Study Drug in DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with adverse events leading to discontinuation of study drug were reported.

Time frame:
From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Discontinuation of Study Drug in DBT Phase
ParticipantsRimegepantPlacebo
Number of Participants With AEs Leading to Discontinuation of Study Drug in DBT Phase42
SecondaryNumber of Participants With AEs Leading to Discontinuation of Study Drug in OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with adverse events leading to discontinuation of study drug were reported.

Time frame:
From Day 1 of OL Rimegepant dosing up at Week 12 to Week 52 (40 weeks)
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Discontinuation of Study Drug in OLE Phase
ParticipantsDBT Rimegepant/OLE RimegepantDBT Placebo/OLE Rimegepant
Number of Participants With AEs Leading to Discontinuation of Study Drug in OLE Phase24
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase: Hematology Parameters

The laboratory parameters were graded according to the National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) version (v)5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Hematology parameters included: eosinophils, hemoglobin (high, low), lymphocytes (high, low), white blood cell count (WBC) (low, high), platelets, and neutrophils. hematocrit, red blood cell count, Number of participants with non-zero laboratory abnormalities of hematology parameters were reported in this outcome measure.

Time frame:
From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase: Hematology Parameters
ParticipantsRimegepantPlacebo
Hemoglobin, low20
Neutrophils40
Platelets10
White blood cell count, low10
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase: Hematology Parameters

The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Hematology parameters included: eosinophils, hemoglobin (high, low), lymphocytes (high, low), WBC (low, high), platelets, and neutrophils. Number of participants with non-zero laboratory abnormalities of hematology parameters were reported in this outcome measure.

Time frame:
From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase: Hematology Parameters
ParticipantsDBT Rimegepant/OLE RimegepantDBT Placebo/OLE Rimegepant
Hemoglobin, low21
Lymphocytes, low11
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase: Serum Chemistry Parameters

The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Serum chemistry parameters included: creatine kinase, low density lipoprotein (LDL) cholesterol, LDL cholesterol, fasting, triglycerides, triglycerides, fasting and not fasting, alanine aminotransferase increased, albumin, alkaline phosphatase, aspartate aminotransferase increased, bicarbonate, bilirubin, calcium (high, low), cholesterol, creatinine, estimated glomerular filtration rate (eGFR), glucose (high, low), lactate dehydrogenase, LDL cholesterol, potassium (high, low), sodium (high, low), and uric acid. Number of participants with non-zero laboratory abnormalities of serum chemistry parameters were reported in this outcome measure.

Time frame:
From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in DBT Phase: Serum Chemistry Parameters
ParticipantsRimegepantPlacebo
Creatine kinase40
LDL cholesterol04
Triglycerides10
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase: Serum Chemistry Parameters

The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE. Grade 4=life-threatening consequences; urgent intervention indicated. Serum chemistry parameters included: creatine kinase, LDL cholesterol, LDL cholesterol, triglycerides, triglycerides, alanine aminotransferase increased, albumin, alkaline phosphatase, aspartate aminotransferase increased, bicarbonate, bilirubin, calcium (high, low), cholesterol, creatinine, eGFR, glucose (high, low), lactate dehydrogenase, potassium (high, low), sodium (high, low), uric acid. Number of participants with non-zero laboratory abnormalities of serum chemistry parameters were reported in this outcome measure.

Time frame:
From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Abnormalities in OLE Phase: Serum Chemistry Parameters
ParticipantsDBT Rimegepant/OLE RimegepantDBT Placebo/OLE Rimegepant
LDL cholesterol77
Triglycerides11
SecondaryNumber of Participants With Grade 3 to 4 Changes in DBT Phase: Urinalysis

The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Urinalysis parameters included: urine glucose and urine protein.

Time frame:
From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Changes in DBT Phase: Urinalysis
ParticipantsRimegepantPlacebo
Number of Participants With Grade 3 to 4 Changes in DBT Phase: Urinalysis00
SecondaryNumber of Participants With Grade 3 to 4 Changes in OLE Phase: Urinalysis

The laboratory parameters were graded according to the NCI CTCAE v5.0 severity grade. Grade 1=mild AE. Grade 2=moderate AE. Grade 3=severe AE and Grade 4=life-threatening consequences; urgent intervention indicated. Urinalysis parameters included: urine glucose and urine protein. Number of participants with non-zero laboratory abnormalities of urinalysis parameters were reported in this outcome measure.

Time frame:
From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Changes in OLE Phase: Urinalysis
ParticipantsDBT Rimegepant/OLE RimegepantDBT Placebo/OLE Rimegepant
Number of Participants With Grade 3 to 4 Changes in OLE Phase: Urinalysis31
SecondaryNumber of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3* Upper Lower Limit of Normal (ULN) Concurrent With Total Bilirubin (TBIL) >2*ULN in DBT Phase

Number of participants with ALT or AST \>3\*ULN concurrent with TBIL \>2\*ULN in DBT phase were reported in this outcome measure.

Time frame:
From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3* Upper Lower Limit of Normal (ULN) Concurrent With Total Bilirubin (TBIL) >2*ULN in DBT Phase
ParticipantsRimegepantPlacebo
Number of Participants With Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) >3* Upper Lower Limit of Normal (ULN) Concurrent With Total Bilirubin (TBIL) >2*ULN in DBT Phase00
SecondaryNumber of Participants With ALT or AST> 3* ULN Concurrent With TBIL >2* ULN in OLE Phase

Number of participants with ALT or AST \>3\*ULN concurrent with TBIL \>2\*ULN in OLE phase were reported in this outcome measure.

Time frame:
From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Reported as:
Count of participants · Participants
Number of Participants With ALT or AST> 3* ULN Concurrent With TBIL >2* ULN in OLE Phase
ParticipantsDBT Rimegepant/OLE RimegepantDBT Placebo/OLE Rimegepant
Number of Participants With ALT or AST> 3* ULN Concurrent With TBIL >2* ULN in OLE Phase00
SecondaryNumber of Participants With Hepatic-related AEs in the DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure.

Time frame:
From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs in the DBT Phase
ParticipantsRimegepantPlacebo
Number of Participants With Hepatic-related AEs in the DBT Phase34
SecondaryNumber of Participants With Hepatic-related AEs in the OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure.

Time frame:
From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs in the OLE Phase
ParticipantsDBT Rimegepant/OLE RimegepantDBT Placebo/OLE Rimegepant
Number of Participants With Hepatic-related AEs in the OLE Phase87
SecondaryNumber of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure. Number of participants with Hepatic-related AEs leading to study drug discontinuation were reported in this outcome measure.

Time frame:
From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the DBT Phase
ParticipantsRimegepantPlacebo
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the DBT Phase01
SecondaryNumber of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. Hepatic AEs included cirrhosis, hepatic failure, hepatitis, jaundice, or liver failure. Number of participants with Hepatic-related AEs leading to study drug discontinuation were reported in this outcome measure.

Time frame:
From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the OLE Phase
ParticipantsDBT Rimegepant/OLE RimegepantDBT Placebo/OLE Rimegepant
Number of Participants With Hepatic-related AEs Leading to Study Drug Discontinuation in the OLE Phase21

Adverse events

Collected over DBT phase: From Day 1 of dosing up to 7 days post last dose of study drug in DBT phase or prior to start of OL rimegepant dose, whichever was earlier (maximum up to 13 weeks); OLE phase: From Day 1 of OL Rimegepant dosing up to 7 days post last dose (maximum up to 41 weeks). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DBT: Rimegepant0/247 (0%)2/247 (0.8%)85/247 (34.4%)
DBT: Placebo0/249 (0%)1/249 (0.4%)73/249 (29.3%)
DBT Rimegepant/OLE Rimegepant0/227 (0%)4/227 (1.8%)148/227 (65.2%)
DBT Placebo/OLE Rimegepant0/231 (0%)0/231 (0%)150/231 (64.9%)
Most frequent serious events
Most frequent serious events
EventDBT: RimegepantDBT: PlaceboDBT Rimegepant/OLE RimegepantDBT Placebo/OLE Rimegepant
ConstipationGastrointestinal disorders0/2470/2491/2270/231
Hepatic function abnormalHepatobiliary disorders0/2470/2491/2270/231
Nodal osteoarthritisMusculoskeletal and connective tissue disorders0/2470/2491/2270/231
Coronavirus infectionInfections and infestations0/2470/2491/2270/231
Pancreatitis acuteGastrointestinal disorders1/2470/2490/2270/231
COVID-19Infections and infestations1/2470/2490/2270/231
AppendicitisInfections and infestations0/2471/2490/2270/231
Most frequent other events
Showing 10 of 59
Most frequent other events
EventDBT: RimegepantDBT: PlaceboDBT Rimegepant/OLE RimegepantDBT Placebo/OLE Rimegepant
NasopharyngitisInfections and infestations21/24725/24951/22764/231
COVID-19Infections and infestations6/2477/24932/22728/231
Back painMusculoskeletal and connective tissue disorders3/2476/24915/2279/231
InfluenzaInfections and infestations5/2475/24911/22714/231
Coronavirus infectionInfections and infestations8/2474/24912/22710/231
PyrexiaGeneral disorders6/2475/2497/22712/231
Oropharyngeal painRespiratory, thoracic and mediastinal disorders9/2478/24911/22710/231
ConstipationGastrointestinal disorders7/2471/2498/2278/231
Dental cariesGastrointestinal disorders1/2473/2498/2274/231
ToothacheGastrointestinal disorders3/2472/2498/2275/231

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RimegepantPlaceboTotal
Mean44.9 ± 9.5243.1 ± 10.6844.0 ± 10.15
Sex: Female, Male
Sex: Female, Male(Participants)RimegepantPlaceboTotal
Female225221446
Male222850
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)RimegepantPlaceboTotal
Count of participants——0
08

Study locations

44 sites
  • Medical Corporation Seikokai Takanoko Hospital
    Matsuyama, Ehime 790-0925, Japan
  • Jinnouchi Neurosurgical Clinic
    Kasuga-shi, Fukuoka 816-0802, Japan
  • Ikeda Neurosurgical Clinic
    Kasuga-shi, Fukuoka 816-0824, Japan
  • SUBARU Health Insurance Society Ota Memorial Hospital
    Ota-shi, Gunma 373-8585, Japan
  • Doi Clinic Internal Medicine/Neurology
    Hiroshima, Hiroshima 730-0031, Japan
  • Japanese Red Cross Asahikawa Hospital
    Asahikawa-shi, Hokkaido 070-8530, Japan
  • Nakamura Memorial Hospital
    Chūōku, Hokkaido 060-8570, Japan
  • Higashi Sapporo Neurology and Neurosurgery Clinic
    Sapporo, Hokkaido 003-0003, Japan
  • Konan Medical Center
    Higashinada-ku, Hyōgo 658-0064, Japan
  • Nishinomiya Munic. Ctr. Hosp.
    Nishinomiya-shi, Hyōgo 663-8014, Japan
  • Mito Kyodo General Hospital
    Mito, Ibaraki 310-0015, Japan
  • Kijima Neurosurgery Clinic
    Kahoku-gun, Ishikawa-ken 929-0342, Japan
  • Iwate Medical University Uchimaru Medical Center
    Morioka, Iwate 020-8505, Japan
  • Atsuchi Neurosurgery Hospital
    Kagoshima, Kagoshima-ken 892-0842, Japan
  • Tanaka Neurosurgical Clinic
    Kagoshima, Kagoshima-ken 892-0844, Japan
  • St. Marianna Univ. Hospital
    Kawasaki-shi, Kanagawa 216-8511, Japan
  • Fujitsu Clinic
    Nakahara, Kanagawa 211-8588, Japan
  • Atago Hospital
    Kochi, Kochi 780-0051, Japan
  • Umenotsuji Clinic
    Kochi, Kochi 780-8011, Japan
  • Saiseikai Kumamoto Hospital
    Kumamoto, Kumamoto 861- 4193, Japan
  • Tatsuoka Neurology Clinic
    Kyoto, Kyoto 600-8811, Japan
  • Sendai Headache and Neurology Clinic, Medical Corporation
    Sendai, Miyagi 982-0014, Japan
  • Ooba Clinic for Neurosurgery & Headache
    Ōita, Oita Prefecture 870-0831, Japan
  • Makabe Clinic
    Okayama, Okayama-ken 700-0964, Japan
  • Okayama City General Medical Center Okayama City Hospital
    Okayama, Okayama-ken 700-8557, Japan
  • Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai
    Osaka, Osaka 530-8480, Japan
  • Tominaga Clinic
    Osaka, Osaka 556-0015, Japan
  • Kindai University Hospital
    Osakasayama-shi, Osaka 589-8511, Japan
  • Takase Intern. Med. Clinic
    Toyonaka-shi, Osaka 560-0012, Japan
  • Saitama Medical University Hospital
    Iruma-gun, Saitama 350-0495, Japan
  • Saitama Neuropsychiatric Institute
    Saitama-shi, Saitama 338-8577, Japan
  • Japanese Red Cross Shizuoka Hospital
    Shizuoka, Shizuoka 420-0853, Japan
  • Dokkyo Medical Univ. Hosp.
    Shimotsuga-gun, Tochigi 321-0293, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Tokai univ. hachioji hosp.
    Hachioji-shi, Tokyo 192-0032, Japan
  • Shinagawa Strings Clinic
    Minato-ku, Tokyo 108-0075, Japan
  • Kitasato University Kitasato Institute Hospital
    Minato-ku, Tokyo 108-8642, Japan
  • USUDA CLINIC for internal medicine
    Setagaya-ku, Tokyo 156-0043, Japan
  • Fukuuchi Pain Clinic
    Shinjuku-ku, Tokyo 160-0017, Japan
  • Keio University Hospital
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Nishiogi Pain Clinic
    Suginami-ku, Tokyo 167-0054, Japan
  • Sakura Neuro Clinic
    Toyama, Toyama 930-0803, Japan
  • Nagamitsu Clinic
    Hofu-shi, Yamaguchi 747-0802, Japan
  • Nagaseki Headache Clinic
    Kai-shi, Yamanashi 400-0124, Japan
09

References and documents

Publications

  • Matsumori Y, Kitamura S, Yamamoto T, Ishikawa T, Hoshino Y, Yoshimatsu H, Thiry A, Arakawa A, Fullerton T, Sakai F, Takeshima T. Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study. J Headache Pain. 2026 Feb 27;27(1):66. doi: 10.1186/s10194-026-02290-6. PubMed 41761058 ↗
  • Kitamura S, Matsumori Y, Yamamoto T, Ishikawa T, Hoshino Y, Yoshimatsu H, Thiry A, Arakawa A, Croop R, Fullerton T, Sakai F, Takeshima T. Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial. Headache. 2025 Sep;65(8):1403-1412. doi: 10.1111/head.14995. Epub 2025 Jun 20. PubMed 40542538 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jan 2024, 17 months.

Results were first posted in Jul 2025, 1 year 5 months after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 17 months is close to that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2022
First posted
Jun 1, 2022
StartActual
Aug 9, 2022
Primary completionActual
Jan 18, 2024
CompletionActual
Nov 7, 2024
Results first posted
Jul 14, 2025
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05399485
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 1, 2022
Start date
Aug 9, 2022
Primary completion
Jan 18, 2024
Completion
Nov 7, 2024
Results posted
Jul 14, 2025
Last update
Nov 18, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion